Table 2.
Incidence of patients that developed cardiac complications. Data are expressed as the number of patients in each group.
| Cardiovascular complications | β-blockers (N = 205) | No β-blockers (N = 315) | p value |
|---|---|---|---|
| Acute coronary syndrome (%) | 1 (0.5%) | 0 (0 %) | n.s. |
| Atrial fibrillation (%) | 29 (14.1%) | 49 (15.6%) | n.s. |
| CHF (%) | 1 (0.5%) | 0 (0%) | n.s. |
| Other | 3 (1.5%) | 3 (0.9%) | n.s. |
| Composite cardiac endpoints | 34 (16.6%) | 52 (16.5%) | n.s. |